Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy

Table 4

Factors related to the improvement of eGFR (CKD-EPI) (increase in eGFR > 10%) according to univariate and multivariate logistic regressions.

Risk factor	Univariate	value	Multivariate	value
	HR (95% CI)		HR (95%CI)
Age: ≥50 years	2.221 (1.070–4.611)	0.032	1.315 (0.576–3.001)	0.516
Sex: male	0.987 (0.423–2.305)	0.976
HBeAg: positive	0.663 (0.308–1.427)	0.293
Cirrhosis	0.785 (0.333–1.849)	0.580
Decompensation	0.929 (0.342–2.520)	0.885
Hepatocellular carcinoma	1.101 (0.338–3.583)	0.873
HBV genotype: type B	0.518 (0.222–1.209)	0.128
Baseline ALT > 200 U/L	1.031 (0.494–2.154)	0.935
Baseline HBV DNA: <7 log IU/mL	1.222 (0.564–2.650)	0.611
Baseline eGFR < 60 mL/min/1.73 m^2	7.117 (1.849–27.399)	0.004	4.560 (1.046–19.875)	0.043
Diabetes mellitus	5.958 (1.776–19.993)	0.004	4.194 (1.165–15.098)	0.028
Hypertension	0.931 (0.436–3.874)	0.864
Add-on adefovir therapy	0.477 (0.186–1.222)	0.123
Complete virological response at month 6	1.670 (0.778–3.585)	0.189
Contrast medium exposure	1.101 (0.338–3.583)	0.873

ALT: alanine transaminase; HBeAg: hepatitis B e-antigen; HR: hazard ratio.